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Abbreviations 
AF: Atrial fibrillation; OAC: oral anticoagulation; NOAC: non-vitamin K antagonist 
oral anticoagulants; mAFA：mobile atrial fibrillation application; QoL: quality of life; 
PPG：photoplethysmography; ECG: electrocardiogram; CHA2DS2-VASc: a history of 
congestive heart failure, hypertension, diabetes, vascular disease (myocardial infarction 
and peripheral artery disease), and female sex (sex category) ; HAS-BLED: 
hypertension, abnormal renal and liver function, stroke, bleeding, labile INRs, elderly, 
drugs or alcohol; SAMe-TT2R2: sex, age, medical history, treatment, tobacco, race; 
TTR：time in therapeutic range；EHRA：European Heart Rhythm Association；NYHA：
New York Heart Assessment；SpO2：Pulse Oxygen Saturation；TIA: transient ischemic 
attack; DVT: deep vein thromboembolism; STEMI: ST-segment elevation myocardial 
infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; HF: heart 
failure; HCRU: HealthCare Resource Utilization; QALY: quality adjusted life year; 
ICER: incremental cost-effectiveness ratio; CHEERS: Consolidated Health Economic 
Evaluation Reporting Standards; ICC: intracluster correlation coefficient; HR: hazard 
ratio. 
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Abstract  
Background  Current management of patients with atrial fibrillation (AF) is limited 
by low detection of AF, nonadherence to guidelines and lack of consideration of 
patient's preferences, thus highlighting the need for a holistic and integrated approach 
to AF management. The present study aims to determine whether a mHealth 
technology-supported AF integrated management strategy will reduce AF-related 
adverse events. 
Methods/design The mAFA II trial is a prospective, cluster randomized controlled trial. 
The 40 sites will be randomized to mAFA-integrated care intervention or usual care 
arms. Prior to randomization, study sites will be paired to be matched in size and the 
proportion of study eligible patients.  All AF patients aged over 18 years old with 
CHA2DS2-VASc score ≥2 will be enrolled.  
Assuming a composite adverse event rate of 10% pre-intervention, reduced to 5% after 
intervention, we aim to recruit 3660 patients assuming a 10% loss to follow-up. The 
primary study endpoint is a composite of stroke/thromboembolism, all-cause death, and 
rehospitalization. Ancillary analyses would determine patient-related outcome 
measures, health economics and cost effectiveness, as well as an embedded qualitative 
study.  
Discussion The mAFA II trial will provide evidence for an integrated care approach to 
holistic AF care, supported by mobile health technology to improve screening, patient 
involvement and optimization of management. 
 
Trial registration WHO  Chinese Clinical Trial Registry, chictr.org.cn (ChiCTR-
OOC-17014138). 
Key words Atrial fibrillation, integrated management, stroke, all-cause death, 
rehospitalization, anticoagulant 
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What is already known about this topic? 
 Current management of patients with atrial fibrillation (AF) is limited by low 
detection of AF, nonadherence to guidelines and lack of consideration of 
patient's preferences. 
 The need for a holistic and integrated approach to AF management, that includes 
stroke prevention, rate or rhythm control for symptom management, and 
associated comorbidity or lifestyle changes. 
 
What does this article add? 
 This article highlights the design of a prospective clinical trial (mAFA II) testing 
a holistic approach to AF management may be simplified into a practical, simple 
ABC pathway (Avoid stroke; Better symptom management; Cardiovascular and 
other comorbidity risk reduction). 
 The mAFA II trial will provide evidence for an integrated care approach to 
holistic AF care, supported by mobile health technology to improve screening, 
patient involvement and optimization of management. 
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Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia globally, with an 
increased risk of mortality and morbidity from stroke and heart failure [1]. Given the 
increasing prevalence and incidence of AF with an ageing population, this arrhythmia 
represents an increasing public health burden. There will be 12.1 to 15.9 million patients 
suffering from AF in the United States by 2050, and 17.9 million people in Europe by 
2060 [2,3].  
 
Given the largest population in developing countries and the increasingly ageing 
population, the burden of AF is greatly increasing in China. Indeed, there has been a 
20-fold increase in AF prevalence and 13-fold rise in AF-related stroke during the last 
11 years in China [4]. We have previously modelled projections for the risks related 
with AF in East Asia, and the burden of ischaemic stroke and death remains large, 
despite the introduction of new guidelines and therapies [5]. 
 
An integrated, structured approach to AF care has been proposed in the 2016 European 
Society of Cardiology (ESC) guidelines on AF management [6], which is consistent 
with the Innovative Care for Chronic Conditions Framework proposal put forward by 
the World Health Organization [7]. Integrated AF care combines patient involvement, 
multidisciplinary teams, and technology tools to achieve all treatment options for AF, 
for example, a structured support for lifestyle changes, anticoagulation, rate control, 
antiarrhythmic drugs, and catheter and surgical interventions [6]. In small sized studies, 
the use of an integrated care approach in AF has been associated with reduced 
cardiovascular hospitalisations and all-cause mortality, but not AF-related 
hospitalisations or cerebrovascular events [8]. 
 
Various comprehensive and complex proposals for integrated care AF management 
have been proposed [9].  This holistic approach to AF management may be simplified 
into a practical, simple ABC pathway (Avoid stroke; Better symptom management; 
Cardiovascular and other comorbidity risk reduction) [10]. A major challenge is how 
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to operationalize the concept of integrated AF care in busy "real-world" clinical practice, 
especially in low-middle income countries. 
 
The individual components of the ABC pathway are facets of a holistic approach to AF 
patient management [10]. For example, stroke prevention with oral anticoagulation 
(OAC) is the cornerstone of AF management [11]. Nonetheless, suboptimal 
thromboprophylaxis in AF patients is highly prevalent in Asian countries [12-15], 
despite the various guidelines on AF management [6,16-18]. Even moving into the new 
era of the non-vitamin K antagonist oral anticoagulants (NOACs), many patients 
remain undertreated in Asia [19].  
 
Nonadherence to AF management guidelines is also common, ranging from 33% to 68% 
in the Middle East/Africa and Asia, respectively [20]. Nevertheless, patient's 
preferences are another important reason for non-adherence of therapy [21]. Indeed, 
optimal stroke prevention relies on patients taking medications properly and 
continuously. A patient with good knowledge of AF is more likely to be concerned 
about a stroke and would want to be involved in joint decision-making for anticoagulant 
treatment [22], thus increasing treatment adherence and persistence. Lifestyle changes 
are also part of this comprehensive approach, whereby healthy lifestyle and addressing 
cardiovascular risk factors may improve uptake of treatments and ultimately, patient 
outcomes [23]. 
 
Besides, a simple and cost-effective approach to AF care, streamlining management 
pathways from the hospital to the home is needed [24]. Furthermore, up to two-thirds 
of AF patients are asymptomatic and have the same risks as symptomatic AF. Detection 
of these AF episodes and initiation of appropriate management could reduce the risks 
of AF-related stroke and other complications [25]. 
 
Novel strategies that incorporate eHealth or mobile Health (mHealth) encompasses the 
use of information and communication technologies in the management of disease, 
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providing innovative solutions to the problem of long-term management after discharge 
[26-27]. Mobile communication and internet service are well established in China, and 
the high penetration rate of mobile devices and communication networks provides an 
excellent foundation and great opportunities for mHealth development, which may 
facilitate the management of AF in China [28]. 
 
In a pilot study, we designed a mHealth technology-supported AF application model 
(mAF App), integrating clinical decision support tools as part of patient clinical 
decision support tools (CHA2DS2-VASc, HAS-BLED, SAMe-TT2R2 scores), 
guideline-based treatment, educational materials and patient involvement strategies 
with self-care protocols and structured follow-up.28 In this first prospective randomized 
trial of mHealth technology in patients with AF, the mAFA (mAF-App I) trial, use of 
the mAF App significantly improved knowledge, drug adherence, quality of life (QoL) 
and anticoagulation satisfaction [28].  
 
The pilot mAFA I trial focused efforts on improving stroke prevention and assessed 
surrogate outcomes. Apart from stroke prevention, symptom management and lifestyle 
changes, as well as management of cardiovascular and other comorbidities are required 
in the content of AF care. Hence, we updated the mAFA platform (mAFA II) with 
integrated care for AF using the ABC pathway, thus providing an opportunity for 
implementing holistic AF integrated management. More recently, emerging evidence 
suggested that photoplethysmography (PPG) could be used for AF screening in large 
population [29,30].   
 
In the mAFA II trial, we would investigate whether implementation of a mHealth 
technology-supported AF screening with PPG29 and integrated ABC strategy could 
reduce AF-related adverse events (stroke/thromboembolism, all-cause death, and 
rehospitalization). Ancillary analyses would determine patient-related outcome 
measures, health economics and cost effectiveness, as well as an embedded qualitative 
study.   
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Methods and Design 
The mAFA II trial is a prospective, cluster randomized controlled trial, conducted in 40 
hospitals and patients will be followed up for one year.  
 
Study population  
Inclusion criteria would include i) patients aged ≥ 18 years old, diagnosed with new-
onset, paroxysmal, persistent or permanent AF confirmed with electrocardiogram (ECG) 
or 24-hour Holter monitors; and ii) CHA2DS2-VASc score ≥ 2. We excluded 
individuals aged <18 years old, those with mechanical prosthetic valve or 
moderate/severe mitral stenosis, unable to provide informed consent, or unable to have 
one year of follow-up for any reason. The patients are enrolled into the mAFA II trial 
from AF screening approach in the general population, as well as Out-patient and In-
patient Departments in participating hospitals.   
 
Patients will be consecutively recruited at each site to ensure representative inclusion 
of the overall population in each practice setting in China. Enrollment occurs between 
June 1, 2018 and December 31, 2019. The flowchart of AF screening and MAFA II 
project is shown in Fig. 1. 
 
AF screening plan 
AF screening with smart devices of PPG technology (Huawei Technologies Co., Ltd., 
Shenzhen, China) will be available for the population aged over 18 years across China.  
 
At least 14-day monitoring with wristband (HUAWEI HONOR BAND 4), wristwatch 
(HUAWEI WATCH GT, HONOR WATCH) (PPG algorithm developed by Huawei), 
will be proposed for the high-risk population for AF (CHA2DS2-VASc ≥2). The patients 
with identified “AF” episodes by PPG algorithm will be further confirmed by the health 
providers with ECG, 24-h Holter among MAFA hospitals. 
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Randomization 
The 40 participating cluster hospitals will be randomized in a 1:1 ratio to receive either 
the mAFA intervention or usual care. A pilot feasibility investigation was carried out 
for possible study sites, with respect to hospitals (size, the volume of patients for the 
study per month), doctors (willingness to be involve in mAFA II, their concerns and 
obstacles to AF management, the possible time doctors would like to spend on patients 
out of discharge, study fees, etc), patient catchment (smart phone use, education level, 
etc.). The sites will be matched based on hospital size and the proportion of enrolled 
patients.  
 
The hospital sizes were classified as ‘big’ hospitals with enrollment of over 20 patients 
per month, and ‘small’ hospitals with enrollment of under 20 patients per month, 
respectively. Our pilot investigation demonstrated that the ratio of big:small hospitals 
was 1:2, thus 142 patients from individual big hospitals and 71 for small hospitals will 
be needed assuming 10% loss of follow-up. 
 
Intervention 
Hospitals randomised to the intervention arm will use the mAFA platform to manage 
AF patients. The mAFA platform provides clinical decision support tools (CHA2DS2-
VASc, HAS-BLED, SAMe-TT2R2 scores), guideline-based treatment 
recommendations, educational materials and patient involvement strategies with self-
care protocols and structured follow-up, to support implementation of the ABC 
pathway for integrated or holistic AF management [Figure 2]. 
 
Avoid stroke 
The dynamic bleeding risk will be monitoring using HAS-BLED score by MAFA 
platform automatically with updated blood pressure, hemoglobin, renal/liver function, 
etc. (Fig.3A). Modifiable bleeding risk factors would be flagged up (for example, 
systolic blood pressure over 160 mmHg), addressed for the patients and doctors. 
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A personalized OACs management would be tailored to the patients. For example, the 
time in therapeutic range (TTR) will be automatically calculated for the patients on 
warfarin (Fig.3B). If the patients were taking dabigatran or rivaroxaban (the only two 
NOACs that are currently approved in China), the relative dose optimisation of taking 
those drugs and the checklist of requirements will be provided by the mAFA app.  
Drug adherence will be recorded, as patients can use the mAFA platform to record their 
dose and drug use. Liver and renal function monitoring plans will be recommended to 
the patients matched the patient’s age, comorbidities, co-medications and the use of 
OACs. 
 
Patient-reported thromboembolism or bleeding events would be captured using the 
structured questionnaire developed by the mAFA platform. Doctors can also 
communicate with patients on these events through instant messages on the mAFA 
platform.  
 
Better symptom management  
The European Heart Rhythm Association (EHRA) AF symptom assessment scale will 
be used for assessing the severity of AF symptom. The smart device with PPG will be 
undertaken for monitoring AF occurrence (Fig. 4). Take the patients with AF ablation 
for example, the reminder would be sent to the patients and doctors for further 
confirmation and management when doubtful “AF” episode were monitored (Fig. 4). 
 
Cardiovascular and other comorbidities risk management 
Blood pressures will be recorded, and suboptimal readings would be ‘flagged up’ for 
optimization of treatment (Fig.5). Heart failure and angina management would be 
optimized, as needed. Primary and secondary prevention drugs (eg. statins, ACE 
inhibitors or angiotensin receptor antagonists) would be optimized for patients with 
comorbidities such as vascular disease. 
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Follow up and study outcomes 
All patients will be followed in the outpatient clinics at 6 and 12 months for clinical 
events. The clinical events will be adjudicated by a clinical events committee. 
 
The primary endpoint is the composite of stroke/thromboembolism, all-cause death, 
and rehospitalization. The thromboembolism endpoint includes ischaemic stroke, 
transient ischemic attack (TIA), pulmonary embolism, deep vein thromboembolism 
(DVT), other thromboembolism (peripheral embolism, atrial thrombus and left atrial 
appendage thrombus, etc.).  All-cause death will include cardiac death, vascular death, 
and non-cardiovascular death. Cardiac death includes death caused by ST-segment 
elevation myocardial infarction /Non-ST-segment elevation myocardial infarction 
(STEMI/NSTEMI), heart failure (HF), arrhythmia, cardiac perforation / tamponade, 
and other deaths of cardiac origin. Vascular death will include death ascribed to 
ischemic stroke, haemorrhagic stroke, systemic haemorrhage, peripheral embolism, and 
pulmonary embolism. Rehospitalization for AF and AF-related complications, will 
include stroke, systemic thromboembolism, angina, STEMI/NSTEMI, HF, etc. 
 
Secondary outcomes will include the following: i) incidence of AF identified in 2 weeks, 
among high-risk population; ii) the change in proportion of patients able to continue 
anticoagulation; iii) the mAFA intervention costs, individual-level HealthCare 
Resource Utilization (HCRU) as well as associated costs, and quality adjusted life year 
(QALY) gained with mAFA use compared to usual care; and iiii) event rates: event rate 
for composite of ischaemic stroke/TIA and systemic thromboembolism, HF, 
cardiovascular death, or rehospitalization for any cause for AF. 
 
mAFA training, data management, monitoring and quality control 
The mAFA trial program will deliver the training on mAF App use for the researchers 
before the study. Self-reported healthcare utilisation including medicine usage, visits 
for AF-related adverse outcomes, hospitalisations, etc. will be assessed by AF cost 
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questionnaires at 6 and 12 months. Patients will also be asked to fill in a patient-specific 
cost diary every month during study period to avoid missing information. 
 
An independent third party (CheckTruth, Ltd, Beijing, China) will monitor the project 
onsite, ensuring health, safety and the relevant rights of subjects are protected.  
Monitoring will also ensure the sites carry out the study according to protocol, the data 
collected are true and accurate, and the site staff and facility meet the protocol 
requirements.  
 
All sites that enroll at least one patient will undergo a data control audit by completing 
a site visit. The visits will spread over the entire study period, with first visit of 
approximately 30% being done around the time of enrollment. In addition, all sites 
would undergo further data monitoring as necessary, based on performance, queries 
initiated or missing data. For the sites undergoing monitoring, the case report forms for 
patients enrolled at site will be monitored for source documentation and accuracy.  
  
Statistical analysis 
Analyses will be conducted according to the intention-to-treat principle [31]. The 
primary analyses of primary, secondary and exploratory outcomes will be based on the 
intention-to-treat population adjusted for the effect of clustering. All primary tests of 
significance will be two-sided with alpha=5%. Frequencies and percentages per group 
as well as hazard ratios with 95% confidence interval (CI) will be reported for binary 
outcomes. Continuous variables and rate variables will be summarized using mean, 
standard deviation as appropriate, and minimum and maximum values. All statistical 
analyses will be completed with IBM SPSS Statistics, version 22.0 (SPSS Inc) 
 
Cox proportional hazard model analysis will be used to assess the effect of mAFA 
intervention on the primary composite outcome of stroke/thromboembolism, all-cause 
death, and rehospitalization. Additionally, the impact of the mAFA intervention on 
clinical outcomes will be explored, including the time to first occurrence of ischaemic 
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stroke/TIA and systemic thromboembolism, rehospitalization, and cardiovascular death 
will be analyzed. Change in proportion of patients on anticoagulation will be evaluated 
with Mantel-Haenszel statistics and adjusted for the effect of clustering. 
 
Subgroup and sensitivity analyses  
The subgroup analyses for the primary and secondary outcomes will be conducted by 
age strata, gender, and educational level. Sensitivity analyses of the primary and 
secondary outcomes will be repeated among all randomized patients without major 
protocol violations and classified according to the intervention to which they were 
randomized. 
 
Health economic evaluation 
The healthcare resource utilization (hospitalizations, physician office visits, etc.) and 
healthcare costs (hospitalizations, primary care, medications, etc) of mAFA and usual 
care will be examined by descriptive statistics.  
 
For mAFA intervention costs, the included costs are those that are likely to differ across 
the mAFA intervention and usual care, specifically the costs of:  
(i) Costs of the mAF app design (for patients and doctors) and also associated Apps 
including AF decision support tool, and other apps to provide stroke and bleeding 
risk calculations.  These costs can be derived from financial statement or unit 
costs multiplied by total personnel-time. 
(ii) Costs resulting from additional time spent by patients in learning the App, 
uploading their laboratory tests, learning educational programs, and their 
involvement with self-care, etc. 
(iii) Costs of the app-integrated Patient’s Educational Program development. 
(iv) Personnel costs spent in double check the structured data and the source 
documentation of mAF App. 
(v) Costs resulting from additional time spent by doctors compared to control group. 
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Protocol-driven costs for research purposes shall not be included, which may also be 
balanced between arms. 
 
mAFA intervention differences in the mean number of health care resources utilized 
and in the average rate per unit of time will be estimated. Further, the longitudinal 
models will be utilized for the analysis of health care resource use data [32]. 
 
The Kaplan–Meier method will be used for the analysis of cost data, considering the 
presence of censoring in the clinical trial data [33]. The cost-effectiveness 
(improvements in life years, quality of life, QALYs, the cost per QALY gained, and the 
incremental cost-effectiveness ratio (ICER) of mAFA compared to usual care will be 
calculated. The economic assessments will be reported in alignment with the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement 
[34]. The bootstrap method will be used to construct the confidence interval for the 
ICER [35]. 
 
Power calculation 
The mAFA II trial power calculation is shown in Fig. 3. An intracluster correlation 
coefficient (ICC) is assumed to be 0.02, and a reduction in stroke risk would be 52% 
after intervention (Hazard ratio, HR 0.48, 95% CI 0.23-0.99) according to a prior study, 
IMPACT-AF [36]. There would be 10% difference of anticoagulant uptake after mAFA 
intervention and after usual care [28], so we will assume baseline anticoagulant use of 
40%, with a post-mAFA intervention use of 60% and a post-control arm rate of 50%, 
respectively. The composite adverse events (stroke/thromboembolism, all-cause death, 
and rehospitalization) is estimated as 10% during first one year with baseline 
anticoagulant use of 40%. Thus, the sample size will be 3294 patients with type I error 
under 5% and power of over 90%. Trends of sample size from cluster randomization 
are seen in Fig. 6. Considering 10% loss to follow-up, a total of 3660 patients will be 
needed, randomized into the mAFA arm and usual care arms [37].  
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Current trial status 
The first patient was enrolled in June 2018, and 1136 AF patients have been enrolled 
into MAFA II trial as of January 31, 2019. Those patients were mostly recruited from 
Out-patient, In-patient Department of hospitals, with some from the AF screening 
approach in the general population, who were confirmed with their AF diagnosis by 
doctors in the mAFA trial hospitals. Enrollment will continue to December 31, 2019, 
and the last follow-up will be completed until December 31, 2020. 
 
There were 32259 subjects participating in the AF screening approach using smart 
devices with PPG until January 15, 2019, and 83 "AF episodes" have been identified 
with the PPG algorithm. Eight subjects (10%) were lost the follow up, while 66 (91%) 
have been confirmed with AF diagnosis with a 12 lead ECG or 24-Holter among those 
with follow-up, and entered into MAFA II trial. 
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Discussion 
 
The increasing global burden of AF leads to a high incidence of stroke, systemic 
embolism, dementia, heart failure, and death. In recent years, new anticoagulant drugs 
(eg. the NOACs) and technologies (cryoballoon ablation, percutaneous left atrial 
appendage occlusion, etc) have been introduced for the treatment of patients with AF.  
Despite this, suboptimal management of AF is still common, and all-cause or 
cardiovascular death remains high amongst the AF population.37 Indeed, death is the 
most frequent adverse event in AF, with CHF, MI, stroke and major bleeding 
contributing to AF mortality [39,40].  
 
The comorbidities associated with the worse outcomes in AF patients are often sub-
optimally treated with guideline-recommended drugs. Thus, AF integrated care has 
been proposed to provide a holistic approach to AF management and improve outcome. 
Integrated AF care requires patient involvement and empowerment, lifestyle changes, 
educational guidance and shared decision-making. Use of new technologies may 
facilitate this, especially in healthcare systems with a high penetration rate of mobile 
devices and communication networks. 
 
This was tested in the pilot mAFA I trial, which was a small study which showed that 
mHealth technology-supported AF management strategy was feasible, effective and 
safe.28 The clinical decision support provided by the mAF App streamlined guideline-
based decision-making for the stroke prevention in patients with AF, and was easily 
handled by doctors and understood by patients. The clinical decision support tools in 
the mAF App automatically assesses stroke and bleeding risk, stratified the patients at 
high-risk of stroke/TE to anticoagulant treatment, while balancing bleeding risks. 
Bleeding risk factors were also labeled and could be reviewed by doctors and patients 
for proactive correction of modifiable risk factors. Personalized choices of OAC could 
also be advised, and if warfarin was being considered (a common option in China, as 
NOACs are not reimbursed), the SAMe-TT2R2 score would help ‘flag up’ those patients 
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are less likely (if score >2) to achieve good anticoagulation control (as reflected by TTR) 
for more regular INR checks, education/counselling, etc – or alternatively, to consider 
a NOAC.  Thus, the mAFA app helps in rational decision-making on anticoagulant 
management options, with patient engagement.  
 
The mAF App then automatically makes a follow-up plan, permitting patient’s self-
monitoring and timely feedback. Indeed, the pilot mAFA study (mAFA I trial) also 
showed that the mAF App-based self-monitoring and feedback enhanced compliance 
and adherence of drug therapy and anti-coagulant satisfaction.28 While the mAFA I 
study focused on stroke/TE prevention, it is well-recognised that interventions beyond 
anticoagulation are needed to further reduce mortality in AF. Thus, the objective of the 
present study (mAFA II) is to develop and implement a holistic approach to integrated 
AF management, covering AF screening, prevention strategies (oral anticoagulation, 
symptom management with rate or rhythm control), and risk factor management with 
the aim of reducing recurrent stroke, HF, rehospitalization, and death, etc.  
 
Screening strategies can improve the detection of AF in high-risk population,29 and 
could modify morbidity and mortality by early institution of preventive therapies, such 
as OAC. Thus, a cost-effective, screening strategy using PPG technology has been 
integrated into the mAFA II study to help improve AF care, using a simple detection 
tool. 
 
Given the limitations of the cluster-randomised study design, some imbalances between 
the intervention and control site populations may occur. However, the fully randomized 
clusters and similar enrolment procedures at intervention and control sites would limit 
this. In addition, AF screening with HUAWEI smart devices will be performed in 
general population across China, then the “doubtful” AF event will be further confirmed 
by doctors in participating mAFA hospitals with an ECG or 24 h-Holter. The AF 
screening application can be freely available on appstore.huawei.com. While we cannot 
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randomize the general population to AF screening or not, the feasibility of AF screening 
with PPG technology among a large population will be tested. 
 
Conclusion 
The mAFA II trial will provide evidence for an integrated care approach to holistic AF 
care, supported by mobile health technology to improve screening, patient involvement 
and optimization of management.  This trial tests an innovative solution to reduce AF-
related stroke/systemic thromboembolism, all-cause death and hospitalisations, with 
associated patient involvement and empowerment, educational guidance and shared 
decision-making. 
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FIGURE LEGENDS 
  
Fig.1 Flowchart of AF screening and mAFA II project. *PPG: Photoplethysmography. 
 
Fig.2 mAFA II study design 
 
Fig.3 mAFA II: AF integrated care pathway A. 3A. Dynamic bleeding monitoring 3B. 
Anticoagulant quality control of TTR. TTR: Time in therapeutic range.  
 
Fig.4 mAFA II: AF integrated care pathway B. 4A. AF risk monitoring with smart 
device with PPG. Green: normal rhythm, Yellow: irregular cardiac rhythm, Red: 
doubted AF episodes. The alert would be sent to the users for further confirmation and 
management when “doubted” AF were monitored. 4B. ECG monitoring. 
 
Fig.5 mAFA II: AF integrated care pathway C. 5A. Systolic blood pressure monitoring 
on PmAFA, while suboptimal readings would be flagged up’for optimization of 
treatment. 5B. Reminders for optimization of blood control on DmAFA. * PmAFA: 
mAFA for patients, DmAFA: mAFA for doctors.  
 
Fig. 6 Sample size calculations for cluster randomization.  
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